Nova Zelândia - inglês - Medsafe (Medicines Safety Authority)

glaxosmithkline nz limited - diphtheria toxoid, adsorbed 2 [iu] (2.5lfu); pertactin 2.5ug; pertussis filamentous haemagglutinin 8ug; pertussis toxoid, adsorbed 8ug; polio virus type 1 40 dagu; polio virus type 2 8 dagu; polio virus type 3 32 dagu; tetanus toxoid 20 [iu] (5lfu) - suspension for injection - 0.5 ml - active: diphtheria toxoid, adsorbed 2 [iu] (2.5lfu) pertactin 2.5ug pertussis filamentous haemagglutinin 8ug pertussis toxoid, adsorbed 8ug polio virus type 1 40 dagu polio virus type 2 8 dagu polio virus type 3 32 dagu tetanus toxoid 20 [iu] (5lfu) excipient: aluminium medium 199 sodium chloride water for injection - boostrix®-ipv is indicated for booster vaccination against diphtheria, tetanus, pertussis and poliomyelitis of individuals from the age of four years onwards. boostrix®-ipv is not intended for primary immunisation.

Israel - inglês - Ministry of Health

padagis israel agencies ltd, israel - tetanus immune globulin (s/d treated) - solution for injection - tetanus immune globulin (s/d treated) 250 u/ml - tetanus immunoglobulin - tetanus immunoglobulin - immunity against tetanus toxin. treatment of active cases of tetanus.

Nova Zelândia - inglês - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - diphtheria toxoid, adsorbed 30 lf u equivalent to not less than 20 iu; haemophilus influenzae type b polysaccharide 12ug ((polyribosylribitol phosphate) conjugated to tetanus protein (22-36 mcg)); hepatitis b virus surface antigen 10ug; pertussis filamentous haemagglutinin 25ug (adsorbed); pertussis toxoid, adsorbed 25ug; polio virus type 1 40 dagu (mahoney); polio virus type 2 8 dagu (mef-1); polio virus type 3 32 dagu (saukett); tetanus toxoid, adsorbed 10 lf u equivalent to not less than 40 iu - suspension for injection - active: diphtheria toxoid, adsorbed 30 lf u equivalent to not less than 20 iu haemophilus influenzae type b polysaccharide 12ug ((polyribosylribitol phosphate) conjugated to tetanus protein (22-36 mcg)) hepatitis b virus surface antigen 10ug pertussis filamentous haemagglutinin 25ug (adsorbed) pertussis toxoid, adsorbed 25ug polio virus type 1 40 dagu (mahoney) polio virus type 2 8 dagu (mef-1) polio virus type 3 32 dagu (saukett) tetanus toxoid, adsorbed 10 lf u equivalent to not less than 40 iu excipient: aluminium hydroxide amino acids dibasic sodium phosphate monobasic potassium phosphate sucrose trometamol water for injection - hexaxim is indicated for vaccination of infants from six weeks of age against diphtheria, tetanus, pertussis, hepatitis b, poliomyelitis and invasive infections caused by haemophilus influenzae type b. use of this vaccine should be in accordance with the national recommendation as per the current immunisation handbook.

Austrália - inglês - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - poliovirus, quantity: 26 dagu; poliovirus, quantity: 7 dagu; pertactin, quantity: 3 microgram; tetanus toxoid, quantity: 20 iu; diphtheria toxoid, quantity: 2 iu; pertussis toxoid, quantity: 2.5 microgram; pertussis filamentous haemagglutinin, quantity: 5 microgram; pertussis fimbriae 2 + 3, quantity: 5 microgram; poliovirus, quantity: 29 dagu - injection, suspension - excipient ingredients: aluminium phosphate; formaldehyde; polysorbate 80; neomycin; water for injections; phenoxyethanol; streptomycin sulfate; polymyxin b sulfate; glutaral; ethanol - adacel polio is indicated for active immunisation against diphtheria, tetanus, pertussis and poliomyelitis in adults, adolescents and children aged 4 years and older as a booster following primary immunisation.,children 4-6 years of age should have already received four doses of dtpa and ipv or opv.,adacel polio is not intended for primary immunisation.,adacel polio may be administered during pregnancy for prevention of pertussis in young infants via transplacental antibody transfer from the pregnant woman to the fetus.,the use of adacel polio should be determined on the basis of official recommendations. for further information, refer to the current immunisation handbook.

Malta - inglês - Medicines Authority

sanofi pasteur 14 espace henry vallée , 69007 lyon, france - tetanus toxoid, diphtheria toxoid, pertussis toxoid, filamentous haemagglutinin, fha, pertactin, fimbriae types, and, aluminium phosphate - suspension for injection in pre-filled syringe - aluminium phosphate 1.5 mg tetanus toxoid 20 iu diphtheria toxoid 2 iu pertussis toxoid 2.5 µg filamentous haemagglutinin (fha) 5 µg pertactin 3 µg fimbriae types 2 and 3 5 µg - vaccines

Malta - inglês - Medicines Authority

sanofi pasteur 14 espace henry vallée , 69007 lyon, france - diphtheria toxoid, tetanus toxoid - suspension for injection - diphtheria toxoid tetanus toxoid - vaccines

Irlanda - inglês - HPRA (Health Products Regulatory Authority)

glaxo laboratories limited - diphtheria and tetanus toxoids - 0.5 millilitre

Irlanda - inglês - HPRA (Health Products Regulatory Authority)

glaxo laboratories limited - diphtheria and tetanus toxoids - 5 millilitre

Irlanda - inglês - HPRA (Health Products Regulatory Authority)

glaxo laboratories limited - diphtheria and tetanus toxoids and pertussis -

Estados Unidos - inglês - NLM (National Library of Medicine)

sanofi pasteur inc. - clostridium tetani toxoid antigen (formaldehyde inactivated) (unii: k3w1n8yp13) (clostridium tetani toxoid antigen (formaldehyde inactivated) - unii:k3w1n8yp13), corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) (unii: irh51qn26h) (corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) - unii:irh51qn26h) - clostridium tetani toxoid antigen (formaldehyde inactivated) 5 [lf] in 0.5 ml - tenivac® is a vaccine indicated for active immunization for the prevention of tetanus and diphtheria in persons 7 years of age and older. a severe allergic reaction (e.g., anaphylaxis) after a previous dose of tenivac or any other tetanus toxoid or diphtheria toxoid-containing vaccine or any other component of this vaccine is a contraindication to administration of tenivac. [see description (11) .] because of uncertainty as to which component of the vaccine may be responsible, none of the components should be administered. alternatively, such individuals may be referred to an allergist for evaluation if further immunizations are to be considered. risk summary all pregnancies have a risk of birth defect, loss, or other adverse outcomes. in the us general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. there are no adequate and well-controlled studies of tenivac administration in pregnant women in t